Stability of mismatch negativity <scp>event‐related</scp> potentials in a multisite study

Roach, Brian J.; Hamilton, Holly; Bachman, Peter; Belger, Ayşenil; Carrión, Ricardo; Duncan, Erica; Johannesen, Jason; Kenney, Joshua; Light, Gregory A.; Niznikiewicz, Margaret; Addington, Jean; Bearden, Carrie E.; Owens, Emily M.; Cadenhead, Kristin S.; Cannon, Tyrone D.; Cornblatt, Barbara A.; McGlashan, Thomas H.; Perkins, Diana O.; Seidman, Larry J.; Tsuang, Ming T.; Walker, Elaine F.; Woods, Scott W.; Mathalon, Daniel H.

doi:10.1002/mpr.1819

Cited by 11 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the test-retest reliability of the proposed biomarker. Generally, previous studies have shown promising results for the MMN, with high intra-class correlation coefficients (up to > 0.90) and other stability measures in both healthy and clinical populations ( Light et al, 2012 ; Roach et al, 2020 ; Wang et al, 2021 ), consistent with the idea that ERPs tend to be idiosyncratic in their expression, but reliable within individuals ( Gaspar et al, 2011 ). However, a dedicated test-retest reliability study for the specific MMN variant in this article has not yet been conducted.…”

Section: Discussionsupporting

confidence: 69%

Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function

Weber

Tomiello

Schöbi

et al. 2022

eLife

View full text Add to dashboard Cite

The auditory mismatch negativity (MMN) has been proposed as a biomarker of NMDA receptor (NMDAR) dysfunction in schizophrenia. Such dysfunction may be caused by aberrant interactions of different neuromodulators with NMDARs, which could explain clinical heterogeneity among patients. In two studies (N=81 each), we used a double-blind placebo-controlled between-subject design to systematically test whether auditory mismatch responses under varying levels of environmental stability are sensitive to diminishing and enhancing cholinergic vs. dopaminergic function. We found a significant drug x mismatch interaction: while the muscarinic acetylcholine receptor antagonist biperiden delayed and topographically shifted mismatch responses, particularly during high stability, this effect could not be detected for amisulpride, a dopamine D2/D3 receptor antagonist. Neither galantamine nor levodopa, which elevate acetylcholine and dopamine levels, respectively, exerted significant effects on MMN. This differential MMN sensitivity to muscarinic versus dopaminergic receptor function may prove useful for developing tests that predict individual treatment responses in schizophrenia.

show abstract

Section: Discussionsupporting

confidence: 69%

Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function

Weber

Tomiello

Schöbi

et al. 2022

eLife

View full text Add to dashboard Cite

show abstract

“…Moreover, there is scant evidence that patients demonstrate surprise to unpredicted information. Instead, a large number of studies has shown decreased, rather than increased, responses to oddballs (i.e., surprising events) in patients (Corcoran et al, 2018; Farkas et al, 2015; Hederih et al, 2021; Koshiyama et al, 2020; Lappe et al, 2013; Neuhaus et al, 2013; Roach et al, 2020). In fact, the relationship between MMN reduction in schizophrenia, and positive symptoms in schizophrenia are unclear.…”

mentioning

confidence: 99%

Volatility of subliminal haptic feedback alters the feeling of control in schizophrenia.

Foerster¹,

Weibel²,

Poncelet³

et al. 2021

Journal of Abnormal Psychology

View full text Add to dashboard Cite

It has been proposed that agency disorders found in schizophrenia rely on aberrant processing of prediction error. Overreactivity to nonpertinent prediction errors may lead to the attribution of one's own actions to an external source. When applied to perception, this could explain hallucinations. However, experiments in motor control or perception have mainly suggested deficient prediction errors. Using a novel approach based on the manipulation of temporal delays, 23 patients with schizophrenia, 18 patients with bipolar disorder, and 22 healthy participants performed a pointing task with a haptic device that provided haptic feedback without or with delays, which were processed consciously (65 ms) or unconsciously (15 ms). The processing of prediction errors was measured via the adaptation of the hand trajectory, that is, the deceleration in anticipation of the surface, and its modulation as a function of recent history (stable or unstable sensory feedback). Agency was evaluated by measuring the participants' feeling of controlling the device. Only patients with schizophrenia reported a decrease in the feeling of control following subliminally delayed haptic feedback and adapted deceleration durations following subliminally delayed haptic feedback. This effect was correlated with positive symptoms. The overreactivity to subliminal delays was present only when delays occurred repeatedly in an unpredictable way, that is, with a volatile distribution. The results suggest that small temporal uncertainties that should be held as negligible, trigger an aberrant overreactivity which could account for hallucinations and alterations of the patients' conscious feeling of control. General Scientific SummaryInsignificantly small temporal uncertainties in the perceptual and motor domains are typically ignored. This study reveals that patients with schizophrenia, but not bipolar disorders, overreact to delays of a few milliseconds in the haptic feedback. They inadequately adapt their movements to delays and their feeling of control decreases. These effects correlate with positive symptoms, suggesting that negligible prediction errors may become salient in an aberrant way and may thus disturb agency.

show abstract

“…This procedure results in an HC MMN mean (SD) z score of 0 (1), with more positive z scores reflecting more deficient (ie, less negative) MMN amplitudes. This approach, which we have used previously, only removes normal aging and site-specific associations while retaining any pathological aging associations in the CHR-P data.…”

Section: Methodsmentioning

confidence: 99%

Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEAlthough clinical criteria for identifying youth at risk for psychosis have been validated, they are not sufficiently accurate for predicting outcomes to inform major treatment decisions. The identification of biomarkers may improve outcome prediction among individuals at clinical high risk for psychosis (CHR-P).OBJECTIVE To examine whether mismatch negativity (MMN) event-related potential amplitude, which is deficient in schizophrenia, is reduced in young people with the CHR-P syndrome and associated with outcomes, accounting for effects of antipsychotic medication use.DESIGN, SETTING, AND PARTICIPANTS MMN data were collected as part of the multisite case-control North American Prodrome Longitudinal Study (NAPLS-2) from 8 university-based outpatient research programs. Baseline MMN data were collected from June 2009 through April 2013. Clinical outcomes were assessed throughout 24 months. Participants were individuals with the CHR-P syndrome and healthy controls with MMN data. Participants with the CHR-P syndrome who developed psychosis (ie, converters) were compared with those who did not develop psychosis (ie, nonconverters) who were followed up for 24 months. Analysis took place between December 2019 and December 2021. MAIN OUTCOMES AND MEASURESElectroencephalography was recorded during a passive auditory oddball paradigm. MMN elicited by duration-, pitch-, and duration + pitch double-deviant tones was measured. RESULTSThe CHR-P group (n = 580; mean [SD] age, 19.24 [4.39] years) included 247 female individuals (42.6%) and the healthy control group (n = 241; mean age, 20.33 [4.74] years) included 114 female individuals (47.3%). In the CHR-P group, 450 (77.6%) were not taking antipsychotic medication at baseline. Baseline MMN amplitudes, irrespective of deviant type, were deficient in future CHR-P converters to psychosis (n = 77, unmedicated n = 54) compared with nonconverters (n = 238, unmedicated n = 190) in both the full sample (d = 0.27) and the unmedicated subsample (d = 0.33). In the full sample, baseline medication status interacted with group and deviant type indicating that double-deviant MMN, compared with single deviants, was reduced in unmedicated converters compared with nonconverters (d = 0.43). Further, within the unmedicated subsample, deficits in double-deviant MMN were most strongly associated with earlier conversion to psychosis (hazard ratio, 1.40 [95% CI, 1.03-1.90]; P = .03], which persisted over and above positive symptom severity.CONCLUSIONS AND RELEVANCE This study found that MMN amplitude deficits were sensitive to future psychosis conversion among individuals at risk of CHR-P, particularly those not taking antipsychotic medication at baseline, although associations were modest. While MMN shows limited promise as a biomarker of psychosis onset on its own, it may contribute novel risk information to multivariate prediction algorithms and serve as a translational neurophysiological target for novel treatment development in a subgroup of at-risk individuals.

show abstract

Stability of mismatch negativity event‐related potentials in a multisite study

Cited by 11 publications

References 55 publications

Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function

Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function

Volatility of subliminal haptic feedback alters the feeling of control in schizophrenia.

Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis

Contact Info

Product

Resources

About